Clostridium botulinum is a taxonomic collection of several distinct species of anaerobic, Gram-positive, spore-forming bacteria which produce the most poisonous substances known, the botulinum neurotoxins (BoNTs) (9) . BoNTs are classified into seven groups (A to G) based on their antigenicity (12) . Four distinct phenotypic groups of C. botulinum (I to IV) have been identified: group I contains proteolytic strains which are able to produce one or more BoNTs of types A, B, and F; group II comprises nonproteolytic strains producing BoNTs of type B, E, or F; group III includes strains which produce BoNT C and D; and group IV strains produce BoNT G (4). Some strains are able to produce toxins in addition to the neurotoxins. C. botulinum type C and D cultures produce a binary C2 toxin in addition to BoNT C and BoNT D (15) .
This binary C2 toxin is composed of the enzyme component C2I, which ADP-ribosylates monomeric G-actin, and the binding and translocation component C2II, which is responsible for the interaction with a eukaryotic cell membrane receptor and the ensuing endocytosis (20) . Previous studies showed that the enzymatic component C2I is an ϳ49-kDa protein, whereas the inactive binding component C2II has a mass of ϳ80 kDa (1, 15) . C2II is activated by proteolytic cleavage of an ϳ20-kDa amino-terminal fragment. The active 60-kDa part of the binding and translocation component forms SDS-stable heptamers, which bind to the surface of target cells through membrane receptors (2) . After binding of C2I to C2II heptamers, the C2 toxin receptor complex is endocytosed (3) . In acidic endosomes, C2II heptamers undergo major conformational changes. A hydrophobic loop from each C2II subunit inserts into the endosomal membrane and forms a pore, which allows translocation of the enzymatic component into the cytosol. Eventually, C2I-catalyzed ADP-ribosylation of actin leads to redistribution of the cytoskeleton and depolymerization of F-actin resulting in cells becoming rounder (17, 22) .
In this work, draft genome sequencing of a C. botulinum type C strain, named 2300, and subsequent annotation of the predicted coding regions led to the detection of an unusual gene coding for the C2II toxin subunit. The molecular features of the respective gene and the functional characterization of the C2 toxin subunit are summarized below.
MATERIALS AND METHODS
DNA extraction from C. botulinum strain (C) 2300. Genomic DNA of C. botulinum strain (C) 2300 was prepared from an overnight culture grown in YTG medium (16) . Cells (20-ml suspension) were harvested by centrifugation for 15 min at 2,790 ϫ g and 4°C. The cell pellet was washed with 10 mM KH 2 PO 4 buffer (pH 7.5) and resuspended in 4 ml STE buffer (6.7% [wt/vol] saccharose, 50 mM Tris, and 1 mM EDTA, pH 8.0) containing 20 mg/ml lysozyme, and the cell suspension was incubated at 37°C for 30 min. Cell lysis was achieved by adding 500 l 10% (wt/vol) SDS solution and by further incubation at 37°C for 10 min. Subsequently, 430 l EDTA (0.5 M) and 36 l Tris-HCl (1.0 M, pH 8.0) and proteinase K solution (Qiagen, Hilden, Germany) were added, followed by incubation for 3 h at 37°C. The genomic DNA was purified by chloroform-isoamylalcohol (24:1) extraction, precipitated with isopropanol, and washed with 70% ethanol.
Draft genome sequencing and annotation of C. botulinum strain (C) 2300. Genomic DNA of C. botulinum strain (C) 2300 was sequenced by applying the whole-genome shotgun approach, using the Genome Sequencer FLX system (Roche Applied Science, Mannheim, Germany). A single-strand template DNA library was established by using 5 g of a genomic DNA sample. Library preparation and subsequent pyrosequencing followed standard protocols provided by the manufacturer. In total, 634,808 reads were obtained with a single sequencing run, and 153,418,896 nucleotides of genomic DNA were detected. The sequence reads were assembled with the Genome Sequencer De Novo Assembler software (Roche Applied Science, Mannheim, Germany), resulting in 154 large genomic contigs (Ն500 nuclotides) with a draft genome size of 2.88 Mb. The draft genome sequence of C. botulinum strain (C) 2300 was uploaded into the database GenDB to perform an automated gene prediction and annotation (13) , leading to 2,746 predicted protein-coding sequences.
PCR amplification, cloning, and DNA sequencing. The preparation of plasmid DNA from Escherichia coli cells was performed by the alkaline lysis technique using the QIAprep Spin miniprep kit (Qiagen, Hilden, Germany). DNA restriction, analysis by agarose gel electrophoresis, and DNA ligation were performed according to standard protocols (19) . The transformation of plasmid DNA was carried out by heat shock transformation with competent E. coli TOP10 cells. DNA amplification was performed with a PTC-100 thermocycler (MJ Search, Waltham, MA) and BioTaq DNA polymerase (Bioline, Luckenwalde, Germany) or Phusion Hot Start high-fidelity DNA polymerase (Finnzymes, Espoo, Finland). PCR products were purified with the PCR purification Spin Kit (Qiagen, Hilden, Germany). All oligonucleotides used in this study were purchased from Operon Biotechnologies, Ebersberg, Germany. The cloning of PCR products was performed in vector plasmid pCR-Blunt II with the Zero Blunt TOPO PCR cloning kit (Invitrogen, Karlsruhe, Germany) by following the manufacturer's protocol. Cloned PCR products were sequenced by IIT Biotech, Bielefeld, Germany. For expression of recombinant C2II, genomic DNA from strain (C) 2300 was used as the template and C2II was amplified by using the following primers: 5ЈC2II-BamHI (GGATCCATGTTAGTTTCAAAATTTGAGAACTCT) and 3ЈC2II-EcoRI (GAATTCCTATAAATCGCCAATCCTAGTCACTT). Afterwards, the PCR product was digested using BamHI and EcoRI and cloned into the pGEX vector system (Pharmacia Biotech, Uppsala, Sweden). The C2II-pGEX-2T plasmid was transformed into chemical competent E. coli TG1 cells. Plasmid DNA was prepared using standard procedures and sequenced to confirm the DNA sequence.
Expression, purification, and activation of C2II. C2I and C2II were expressed in E. coli BL21(DE3) as recombinant glutathione S-transferase fusion proteins and purified by affinity chromatography with glutathione-Sepharose 4B according to the manufacturer's instructions (11) . Glutathione S-transferase was cleaved off by thrombin (3.25 NIH units/ml of bead suspension) followed by inactivation of thrombin by use of benzamidine beads. C2II was activated with 0.13 g of trypsin per g of total protein for 30 min at room temperature. The active forms of C2II (C2IIa and ⌬C2IIa, the active recombinant short version of C2II) were used in all experiments.
Cell culture and cytotoxicity assay. CaCo-2 cells were cultivated in Dulbecco's minimum Eagle's medium, HT-29 cells were cultivated in McCoy's 5A medium, HeLa cells were cultivated in Dulbecco's modified Eagle's medium, and Chinese hamster ovary CHO-K1 and CHO-RK14 cells were cultivated in Ham's F-12-Dulbecco's minimum Eagle's medium (MEM) (1:1). All media contained 2 mM L-glutamate, 100 units/ml penicillin, 100 g/ml streptomycin, and 10% fetal calf serum (FCS). Cells were routinely kept in tissue culture flasks at 37°C and 5% CO 2 and were trypsinized and replated twice per week. For cytotoxicity experiments, cells were replated in 12-well dishes. After the dishes were washed with phosphatebuffered saline (PBS), the medium was changed to serum-free medium (for CHO-K1 and CHO-RK14 cells) or medium with FCS (for CaCo-2 and HeLa cells).
TER assay. For the transepithelial resistance (TER) assay, CaCo-2 cells were plated on Falcon cell culture inserts and incubated for 5 to 7 days with medium exchange every 3 days. Assays were performed when TER values reached ϳ1,800 to 2,000 ⍀ ⅐ cm 2 . TER was determined using a resistance system for electrophysiological readings of filter cups (Endohm-12; World Precision Instruments, Sarasota, FL). To avoid a drastic drop in the starting TER, all washing and incubation steps were carried out using medium supplemented with 10% FCS. Activated C2II (500 pM) (⌬C2IIa and C2IIa) and C2I (215 pM) were applied to the upper compartment of the Falcon cell culture inserts, and the resulting decrease in TER was monitored for up to 480 min.
In vivo pore-forming assay.
86
Rb ϩ release experiments were performed as described recently (11) . HT-29 cells were plated in complete medium containing 86 Rb ϩ (1 Ci/ml) at a density of ϳ2 ϫ 10 5 cells/well in 24-well cell culture plates. After 48 h, cells were washed twice with PBS and cooled to 4°C. Afterwards, fresh medium (4°C, without serum), containing activated C2II (⌬C2IIa and C2IIa), was added. Proteins were allowed to bind for 45 min at 4°C, followed by washing twice with cold medium to remove unbound toxin. To initiate membrane insertion of the toxins, warm medium (37°C; without serum, pH 4.8) was applied, and cells were incubated for 5 min at 37°C. After a shift back to 4°C, incubation was continued for 40 min at low temperature to allow Nucleotide sequence accession number. The sequence for the C2II component of C2 toxin from C. botulinum strain (C) 2300 was deposited in the GenBank database under accession number GU108606.
RESULTS

Detection of a C2II protein with a C-terminal extension.
After sequencing and annotation of the C. botulinum strain (C) 2300 draft genome, the genes encoding the C2 toxin were identified and further characterized. The nucleotide sequence of the enzymatic component of C2 toxin, C2I, was compared with previously published sequences deposited in GenBank. As expected, the C2I gene of C. botulinum strain (C) 2300 revealed 97 to 99% nucleotide sequence identity with the respective C2I gene from BoNT type C strains 203U28 (8) and 468 (18) and with BoNT type D strain 1873 (18) . An amino acid sequence comparison revealed the highest similarity between C2I of C. botulinum strains (C) 2300 and 203U28 (8) , with only 18 amino acid mismatches in the complete coding region of 431 amino acids (Table 1) . This means a similarity of 95%.
Likewise, the C2II gene and the deduced C2II protein of C. botulinum strain (C) 2300 were compared with their homologous counterparts from strains (C) 203U28 (10), (C) 468 (18) , and (D) 1873 (18) deposited in the GenBank database. Surprisingly, the amino acid sequence alignment of the C2II proteins revealed the presence of a putative 129-amino-acid extension at the C terminus of the C2II protein of C. botulinum strain (C) 2300 (Fig. 1) , whereas the amino-terminal portions of the C2II proteins were highly similar. When comparing the C2II protein of C. botulinum strain (C) 2300 with that of strain 203U28, for instance, an identity of the common part of 98% was determined. Only 20 mismatches were detected (Table 1) . Likewise, a comparison of the nucleotide sequences of the C2II coding regions showed a high level of nucleotide sequence identity over the entire length of hitherto known C2II genes ( Table 2) . Mismatches in this common part of the C2II genes comprise 56 to 68 nucleotides, thus leading to sequence similarities ranging from 96 to 98% in a comparison with nucleotides 1 to 2166 of the C2II gene from C. botulinum strain (C) 2300. However, at this position of the C2II gene of C. botulinum strain (C) 2300, we observed the presence of four additional nucleotides in the alignment (Fig. 2) , apparently resulting in a putative frameshift of the coding region. To verify the nucleotide sequence obtained by pyrosequencing, the C2II gene of C. botulinum strain (C) 2300 was amplified by PCR from genomic DNA data, cloned into the plasmid vector pCR-Blunt II, and resequenced by means of Sanger technology (data not shown). This control assay confirmed the initially obtained sequence of the C2II gene from C. botulinum strain (C) 2300.
The C2II extension is similar to the C-terminal domain of the binding and translocation component. To further analyze the differences in length of the C2II gene from C. botulinum strain (C) 2300 and that from other strains, we compared the nucleotide sequences detected downstream of the stop codons of C2II genes (Fig. 2) . These data indicated clear differences between hitherto described C2II genes and that detected in the genome of C. botulinum strain (C) 2300. This observation supports the view that the differences do not represent a frameshift in the C. botulinum strain (C) 2300 gene sequence but are indicative of a C-terminal extension. To investigate the role of this putative C-terminal extension of the C2II protein, this protein stretch was compared by BLASTP with proteins deposited in GenBank. Surprisingly, we thereby detected that the extension exhibits significant similarity to the C-terminal part of C2II proteins. We found for instance a 57% amino acid sequence similarity to the C-terminal part of C2II protein from strain (C) 203U28 (Fig. 3) . The similarity between the proteins begins at amino acid 586 of the binding and translocation component in strain (C) 203U28. From the 134-amino-acid C terminus of the long version of C2II, 77 amino acids concur with the C-terminal part of the short-version protein. Furthermore, there are 25 amino acid substitutions which probably do not change the chemical properties of the protein. The similarity of the extension in C2II from Clostridium botulinum strain (C) 2300 (amino acids 716 to 850) to the region from amino acid 586 to 720 of the same protein is also shown in Fig.  3 . Comparison of those internal parts of the long-version protein reveals an identity of 58%. These data suggest that the extended region of the C2II protein from C. botulinum strain (C) 2300 can be caused by protein domain duplication.
As no DNA sequence downstream of the C2II gene from C. botulinum strain (C) 92-13 was available from the GenBank database entry, the complete C2II coding region of this strain was amplified by PCR from genomic DNA, and the nucleotide sequence of the PCR product was subsequently determined. C. botulinum strain (C) 92-13 was previously used for the detailed molecular characterization of the C2 toxin (14) . Interestingly, the PCR product generated on (C) 92-13 DNA was the same size as that deduced from the extended C2II gene of C. botulinum strain (C) 2300 DNA (ϳ2,500 bp) (data not shown). This observation was confirmed at the nucleotide level after Sanger sequencing of the PCR product, revealing that both genes are almost identical and that both are characterized by a 3Ј extension of the C2II coding region (Fig. 2) . These data suggest that the extended version of the C2II gene initially detected in the genome of C. botulinum strain (C) 2300 is also present in other environmental isolates and that at least two types of the C2II proteins exist in nature. In previous studies, C2II from strain (C) 92-13 was amplified from genomic DNA according to the sequence of C2II from strain (C) 203U28 and therefore only a partial C2II protein was expressed and purified (2) . Based on these findings, recombinant C2II from strain (C) 92-13 is termed ⌬C2IIa.
Intoxication efficiency of recombinant ⌬C2IIa (strain [C] 92-13) and C2IIa (strain [C] 2300). Because the C-terminal extension in C2II of C. botulinum strain (C) 2300 is similar to the receptor-binding domain of other C2II proteins (e.g., strain [C] 203U28), we investigated a possible effect of this extension on the intoxication efficiency in cell culture. To compare the impacts of the different versions of C2II on the disruption of the actin cytoskeleton by the toxin, we employed fluorescence microscopy (Fig. 4) . HeLa cells were treated with C2I (430 pM) and C2IIa (strain [C] 2300) or ⌬C2IIa (strain [C] 92-13) (each 1 nM). The cells were fixed at intervals of 1 h, and the actin cytoskeleton was stained with TRITC-conjugated phalloidin to obtain a time course of the induced morphological changes. After 2 h of intoxication, most C2IIa-treated cells started to become rounder or revealed unstructured dots of F-actin in their cytoplasm. Most ⌬C2IIa-treated cells showed no signs of intoxication at this time point. Intoxication of ⌬C2IIa-treated cells started with an approximate delay of 1 h. After 3 h, all C2IIa-treated cells became round. A comparable intoxication with ⌬C2IIa took 5 h. C2I alone caused no intoxication. These data suggest that the extension in C2II leads to a faster intoxication of HeLa cells.
A more sensitive method for monitoring cell intoxication by clostridial toxins is the measurement of the TER in cell monolayers. For that, CaCo-2 cells were grown on filters until the starting resistance reached around 1,800 to 2,000 ⍀ ⅐ cm 2 . C2I (215 pM) and C2IIa or ⌬C2IIa (each 500 pM) were applied to the apical reservoir. Cell intoxication (i.e., TER decrease) was monitored for up to 8 h, and TER values are shown as the percentage of starting resistance. As shown in Fig. 5A, ⌬C2IIa and C2I abolished TER with a half-time of 190 min, whereas C2IIa and C2I decreased TER with a half-time of 115 min. These data indicate again that the extension in C2II leads to an accelerated cell intoxication. A similar result was obtained by intoxication of wild-type CHO-K1 and C2 toxin-resistant CHO-RK14 cells (Fig. 5B) . After 3 h of intoxication, C2IIa induced more rounding of CHO-K1 cells than ⌬C2IIa. CHO-RK14 cells are deficient in binding C2 toxin in the 2 nM range (7). Interestingly, ⌬C2IIa already induced cell rounding at 1 To analyze the pore formation of ⌬C2IIa and C2IIa at cell membranes, endosomal conditions can be mimicked by extracellular acidification (5, 11) . To this end, HT-29 cells were preloaded overnight with 86 Rb ϩ ions prior to treatment with various concentrations of ⌬C2IIa or C2IIa on ice. Subsequently, a pH shift of the culture medium mimicking the en -FIG. 3 . Alignment of three amino acid sequences of C2II from Clostridium botulinum strain (C) 2300 and from Clostridium botulinum strain (C) 203U28. The amino acid sequence designated 2300ex from C2II of Clostridium botulinum strain (C) 2300 (amino acids 716 to 847) represents the C-terminal extension of C2II. The amino acid sequence designated 2300 is derived from the same strain and covers the amino acids 586 to 720. The amino acid sequence designated 203U28 is the C-terminal part of C2II of Clostridium botulinum (C) strain 203U28. This alignment was done with ClustalX (21) . Three characters are used to mark conserved positions: an asterisk indicates positions which have a single, fully conserved residue; a colon indicates that one of the "strong" STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, and FYW groups is fully conserved; a period indicates that one of the "weaker" CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, FVLIM, and HFY groups is fully conserved. These are all the positively scoring groups that occur in the Gonnet Pam 250 matrix. The strong and weak groups are defined by a score of Ͼ0.5 and a score of Ͻ0.5, respectively. dosomal conditions allowed the membrane insertion of the heptameric binding component, followed by pore formation and 86 Rb ϩ ion release. As expected, C2IIa caused a stronger release than ⌬C2IIa (Fig. 6 ). Whereas 0.5 nM C2IIa induced a significant release of 86 Rb ϩ ions, 1 to 2 nM ⌬C2IIa was needed to get a similar release.
DISCUSSION
During manual annotation of predicted coding regions in C. botulinum strain (C) 2300, the gene for the binding and translocation component of the C2 toxin attracted attention (C2II), because the length of this gene was about 2,553 nucleotides. Different BLAST hits indicated that other strains in GenBank possess only a short version (2,166 nucleotides) of the C2II component. An extended version of the binding and translocation component was identified in C. botulinum strain (C) 2300 and (C) 92-13. Further analysis revealed that the additional C-terminal part exhibited significant sequence similarity with the known C terminus of C2II, suggesting a domain duplication as the reason for the extension.
C2II exhibits significant sequence similarity with the binding components of other actin-ADP-ribosylating toxins like C. perfringens iota toxin or C. difficile transferase (CDT) (1) and is also highly similar to the protective antigen (PA) of anthrax toxin (23) . All of these toxin components consist of four domains which are suggested to be involved in activation (domain 1), pore formation (domain 2), self-association (domain 3), and binding to the cellular receptor (domain 4) (1).
Noteworthy, the amino acid sequences of domains 1 to 3 are highly similar between the toxins, whereas domain 4, which is responsible for receptor interaction, is different. In the present study, this receptor-binding domain was found to be extended in the C2II isoforms described here. Recently, the crystal structure of the short form of C2II has been reported (20) . In this report, the receptor domain (domain 4) of C2II was unstructured. Our present study may offer an explanation for this result. The short C2II protein version may contain only a part of the receptor domain, which, therefore, remained unstructured under the crystallization conditions. When the receptor domain is changed, the question arises as to whether the biological activity of the toxin is also affected.
Our studies of the activities of the short and long forms of C2 toxin on intoxication of cells and on the decrease in transepithelial electrical resistance of cell monolayers clearly show that the long form of C2II causes stronger effects. First, the rounding of cells occurred earlier with the long form than with the short form of the toxin, and second, the decrease in TER was more rapidly induced by the long form of the toxin than by the short version.
It has been reported that C2II binds to asparagine-linked complex and hybrid carbohydrates (6). Here we used a mutant Chinese hamster ovary cell line which is deficient in N-acetylglucosaminyltransferase I and, therefore, largely resistant to C2 toxin for studies on the sensitivity toward the toxins. Both the short and large forms of C2 toxin were much less toxic toward these mutant cells than to wild-type control cells. Although cell sensitivities toward the toxins were different, these findings suggest that both forms of toxin bind to the same type Asterisks indicate significant differences ( ** , P Ͻ 0.02; *** , P Ͻ 0.001) calculated by analysis of variance (ANOVA). (B) CHO-K1 (f, OE) and CHO-RK14 (Ⅺ, ‚) cells were treated with C2IIa (f, Ⅺ) or ⌬C2IIa (OE, ‚) at the indicated concentrations. C2I was added to C2IIa or ⌬C2IIa at a ratio of 3:7. Cells were further incubated at 37°C, and after 3 h, pictures were taken. The percentage of round cells per field (ϳ300 cells/field) is given as the mean Ϯ SD (n ϭ 3).
FIG. 6.
Comparison of pore formation by C2IIa and ⌬C2IIa in HT-29 cells. Cell monolayers in 24-well culture plates were preloaded with 86 Rb ϩ (1 Ci/ml) for 48 h and, thereafter, washed twice with PBS. Subsequently, C2IIa (f) or ⌬C2IIa (‚) was allowed to bind at 4°C for 45 min. As a control, 20 nM C2I (छ) was used. Afterwards, cells were exposed for 5 min to an acidic shift (pH 4.8) at 37°C to initiate membrane insertion of C2II and ⌬C2IIa. After an additional incubation of 40 min at 4°C, the radioactivity in the medium was measured by using liquid scintillation counting. Asterisks indicate significant differences ( ** , P Ͻ 0.02; *** , P Ͻ 0.001) calculated by ANOVA.
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on April 15, 2013 by UNIV KLINIKUM FREIBURG http://iai.asm.org/ of receptor. Binding of C2 toxin to carbohydrate structures is most likely polyvalent (note the heptameric structure of activated C2II). Therefore, we propose that the short and long forms of the toxin can bind to the same receptor but with different affinities, resulting in different biological effects. However, direct receptor-binding studies are necessary to support the view that variation of the receptor domain has consequences for the receptor affinity of the toxin. Taken together, we report on a novel long version of the binding component of C2 toxin in C. botulinum strain (C) 2300. It appears that C2 toxin from strain (C) 92-13, which is frequently used in biological studies of C2 toxin, is also a longversion toxin which is characterized by an extension of the receptor domain, resulting in increased biological activity most likely due to increased receptor binding.
